Should I Buy CTOR? CTOR 2026 Analysis

Should You Buy Citius Oncology Inc (CTOR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.100

1 Day change

52 Week Range

6.190

Analysis Updated At

2026/01/25

Citius Oncology Inc (CTOR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive financial performance, absence of significant trading trends, and no recent news or catalysts make this stock less appealing for immediate investment. Additionally, technical indicators and proprietary trading signals do not suggest a compelling entry point.

Technical Analysis

The MACD histogram is positive and expanding, which is a mild bullish signal. RSI is neutral at 56.824, indicating no overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. Key support and resistance levels are at Pivot: 1.096, R1: 1.163, S1: 1.029, R2: 1.204, and S2: 0.988, showing limited upward momentum.

Options Data

Positive Catalysts

2026/01/25 23:06:03

NULL identified. No recent news or significant insider/hedge fund activity.

Neutral/Negative Catalysts

2026/01/25 23:06:03

No recent news or events to drive investor sentiment.

Financial Performance

In Q4 2025, the company reported zero revenue growth, a significant drop in net income to -$4,996,656 (-77.17% YoY), and a decline in EPS to -0.06 (-80.65% YoY). Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes available.

1 Analyst Rating

Wall Street analysts forecast CTOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTOR is 6 USD with a low forecast of 6 USD and a high forecast of 6 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.100

Low

Averages

High

Current: 1.100

Low

Averages

High

Maxim

Michael Okunewitch

Hold

Buy

upgrade

AI Analysis

2025-09-23

Reason

Maxim

Michael Okunewitch

Price Target

AI Analysis

2025-09-23

upgrade

Hold

Buy

Reason

Maxim analyst Michael Okunewitch upgraded Citius Oncology to Buy from Hold with a $6 price target.

Maxim

Hold

Buy

upgrade

2025-09-23

Reason

Maxim

Price Target

2025-09-23

upgrade

Hold

Buy

Reason

Maxim upgraded Citius Oncology to Buy from Hold with a $6 price target. The company has taken key steps to address its capital needs and now should have a path to launching Lymphir in Q4 of this year, which is a \"key event\" for Citius, the analyst tells investors in a research note. Cutaneous T-cell lymphoma is a relatively small and concentrated market, which should support pricing of about $300K per course of treatment, and the firm believes that sales could \"ramp quickly\" in 2026, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CTOR

Unlock Now

CTOR Should I Buy

CTOR Should I Buy

Should You Buy Citius Oncology Inc (CTOR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch